Business
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J., July 15, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company’s proprietary ai²™ division.
About this update from Apimeds Pharmaceuticals Us, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":384,"url":"https://media.zenfs.com/en/business-wire.com/b0b27a408dfd7dda8bcf008ebb10f5b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xNNqCp9YdL9GMn22MPaVlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0b27a408dfd7dda8bcf008ebb10f5b9","width":480,"height":384}},"lazy":false},{"type":"text","content":"MATAWAN, N.J., July 15, 2025--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company’s proprietary ai²™ division.","length":498,"tagName":"p"},{"type":"text","content":"Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Mr. Peters, previously Chief Strategy & Insights Officer at Heller Agency, has a proven track record in healthcare innovation, strategic communications, and KOL engagement.","length":401,"tagName":"p"},{"type":"text","content":"In their new roles, Dr. Kramer will oversee all product development activities at Apimeds, while Mr. Peters will lead the strategy, positioning, and launch of the Company’s ai²™ platform.","length":187,"tagName":"p"},{"type":"text","content":""We’re thrilled to welcome Susan and Brian to the Apimeds leadership team," said Erik Emerson, Chief Executive Officer of Apimeds. "Strengthening our operational leadership has been a priority since our IPO. Susan enhances our clinical development capabilities at a pivotal time for Apitox, while Brian brings vision, energy, and deep strategic expertise as we build and scale our ai²™ platform."","length":416,"tagName":"p"},{"type":"text","content":""Apitox is an incredibly exciting program," said Dr. Kramer. "Having worked with Erik in the past, I know the caliber of hi...